Article Title: More uncertainty at FDA as Pazdur plans to resign
Publication Date: Tue, 02 Dec 2025
As relayed by BioWorld on December 2, 2025, the U.S. Food and Drug Administration (FDA) faces further instability, as Richard Pazdur, director of the FDA’s CDER (Centre for Drug Evaluation and Research), announced his intention to retire by year-end. This announcement comes just three weeks after he accepted the position.
Richard Pazdur’s sudden retirement decision is a significant event as he has held crucial roles in the agency and his departure may leave a considerable void in the CDER. Pazdur’s position at the FDA’s CDER holds considerable influence over the approval of new medicines in the U.S, shaping the approach toward emergent drug and therapies.
The succession planning and appointment of a new director will undoubtedly be a major focus for FDA going forward, as the role requires extensive knowledge and experience in drug evaluation. The decision also amplifies the existing uncertainty at the regulatory body, adding pressure to ensure smooth transitions and maintain the public’s confidence in FDA’s operations.
For biotech investors and companies, this development underlines the potential for fluctuations in the regulatory environment. As the FDA grapples with leadership changes, companies moving towards FDA approval could face unexpected challenges or delays. Likewise, this change might affect those companies undergoing the drug evaluation process.
In conclusion, Pazdur’s retirement could potentially shape the industry’s outlook based on how quickly an apt successor is found and the approach they take towards drug approval. Industry participants should keep abreast of these developments as they unfold. Rest assured, Industry Informant will continue to provide essential updates and valuable insights into these and other key biotech industry events.
